News | June 23, 2026
WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center
Clearing 19 biologics for Europe market
Clearing 19 biologics for Europe market
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Patalganga plant received zero observation from USFDA earlier
Platform integrates VR simulations and AI-driven coaching to build job-ready skills in pharma manufacturing
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
